Growth • Sanofi
SNY
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
3,3%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
5,5%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
14,7%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
14,7%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
1,5%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
3,2%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!